Tuesday, October 8, 2013
• Cardiome Pharma Corp., of Vancouver, British Columbia, said data from an observational, retrospective study including 251 recent-onset atrial fibrillation (AF) patients receiving Brinavess (vernakalant) treatments during the period between Jan. 15, 2011, and April 15, 2013, showed that 70 percent converted with a median time of 11 minutes.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.